NDAORALCAPSULEPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
6/8 — Strong
Priority Review
LUPKYNIS (voclosporin) by Aurinia Pharmaceuticals is calcineurin inhibitors [moa]. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUPKYNIS (voclosporin) is an oral calcineurin inhibitor immunosuppressant approved in 2021 for lupus nephritis. It works by inhibiting calcineurin-dependent T-cell activation, reducing immune-mediated kidney inflammation. Voclosporin represents a targeted approach to managing a serious autoimmune complication in systemic lupus erythematosus patients.
$0.020BPart D
Peak11.5 years to LOEThe product is in peak lifecycle with modest Part D spending ($20M) and 1,676 claims in 2023, suggesting a stable but niche market with room for commercial team growth in patient access and awareness.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Started Apr 2026
150 enrolled
Lupus Nephritis
LUPKYNIS Drug-use Results Survey
Started Sep 2025
400 enrolled
Lupus Nephritis
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
Started Mar 2024
4 enrolled
Adolescent Lupus NephritisPediatric Lupus Nephritis
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
Started Oct 2023
9 enrolled
Adolescent Lupus NephritisPediatric Lupus Nephritis
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
Started Apr 2022
229 enrolled
Lupus Nephritis
Worked on LUPKYNIS at Aurinia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.